Minlikeeva Albina N, Freudenheim Jo L, Cannioto Rikki A, Szender J Brian, Eng Kevin H, Modugno Francesmary, Ness Roberta B, LaMonte Michael J, Friel Grace, Segal Brahm H, Odunsi Kunle, Mayor Paul, Zsiros Emese, Schmalfeldt Barbara, Klapdor Rüdiger, Dӧrk Thilo, Hillemanns Peter, Kelemen Linda E, Kӧbel Martin, Steed Helen, de Fazio Anna, Jordan Susan J, Nagle Christina M, Risch Harvey A, Rossing Mary Anne, Doherty Jennifer A, Goodman Marc T, Edwards Robert, Matsuo Keitaro, Mizuno Mika, Karlan Beth Y, Kjær Susanne K, Høgdall Estrid, Jensen Allan, Schildkraut Joellen M, Terry Kathryn L, Cramer Daniel W, Bandera Elisa V, Paddock Lisa E, Kiemeney Lambertus A, Massuger Leon F, Kupryjanczyk Jolanta, Berchuck Andrew, Chang-Claude Jenny, Diergaarde Brenda, Webb Penelope M, Moysich Kirsten B
Deparment of Cancer Prevention and Control, Roswell Park Cancer Institute, A-352 Carlton House, Elm and Carlton Streets, Buffalo, NY, 14263, USA.
Deparment of Epidemiology and Environmental Health, University at Buffalo, Buffalo, NY, USA.
Cancer Causes Control. 2017 May;28(5):469-486. doi: 10.1007/s10552-017-0867-1. Epub 2017 Mar 14.
Survival following ovarian cancer diagnosis is generally low; understanding factors related to prognosis could be important to optimize treatment. The role of previously diagnosed comorbidities and use of medications for those conditions in relation to prognosis for ovarian cancer patients has not been studied extensively, particularly according to histological subtype.
Using pooled data from fifteen studies participating in the Ovarian Cancer Association Consortium, we examined the associations between history of hypertension, heart disease, diabetes, and medications taken for these conditions and overall survival (OS) and progression-free survival (PFS) among patients diagnosed with invasive epithelial ovarian carcinoma. We used Cox proportional hazards regression models adjusted for age and stage to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) overall and within strata of histological subtypes.
History of diabetes was associated with increased risk of mortality (n = 7,674; HR = 1.12; 95% CI = 1.01-1.25). No significant mortality associations were observed for hypertension (n = 6,482; HR = 0.95; 95% CI = 0.88-1.02) or heart disease (n = 4,252; HR = 1.05; 95% CI = 0.87-1.27). No association of these comorbidities was found with PFS in the overall study population. However, among patients with endometrioid tumors, hypertension was associated with lower risk of progression (n = 339, HR = 0.54; 95% CI = 0.35-0.84). Comorbidity was not associated with OS or PFS for any of the other histological subtypes. Ever use of beta blockers, oral antidiabetic medications, and insulin was associated with increased mortality, HR = 1.20; 95% CI = 1.03-1.40, HR = 1.28; 95% CI = 1.05-1.55, and HR = 1.63; 95% CI = 1.20-2.20, respectively. Ever use of diuretics was inversely associated with mortality, HR = 0.71; 95% CI = 0.53-0.94.
Histories of hypertension, diabetes, and use of diuretics, beta blockers, insulin, and oral antidiabetic medications may influence the survival of ovarian cancer patients. Understanding mechanisms for these observations could provide insight regarding treatment.
卵巢癌确诊后的生存率普遍较低;了解与预后相关的因素对于优化治疗可能至关重要。先前诊断的合并症及其相关药物治疗对卵巢癌患者预后的作用尚未得到广泛研究,尤其是根据组织学亚型进行的研究。
利用参与卵巢癌协会联盟的15项研究的汇总数据,我们研究了高血压、心脏病、糖尿病病史以及针对这些疾病所服用药物与侵袭性上皮性卵巢癌患者的总生存期(OS)和无进展生存期(PFS)之间的关联。我们使用经年龄和分期调整的Cox比例风险回归模型来估计总人群以及组织学亚型分层内的风险比(HRs)和95%置信区间(CIs)。
糖尿病病史与死亡风险增加相关(n = 7674;HR = 1.12;95% CI = 1.01 - 1.25)。未观察到高血压(n = 6482;HR = 0.95;95% CI = 0.88 - 1.02)或心脏病(n = 4252;HR = 1.05;95% CI = 0.87 - 1.27)与死亡率有显著关联。在整个研究人群中,未发现这些合并症与PFS有关联。然而,在子宫内膜样肿瘤患者中,高血压与疾病进展风险较低相关(n = 339,HR = 0.54;95% CI = 0.35 - 0.84)。对于任何其他组织学亚型,合并症均与OS或PFS无关。曾经使用β受体阻滞剂、口服抗糖尿病药物和胰岛素与死亡率增加相关,HR分别为1.20;95% CI = 1.03 - 1.40、1.28;95% CI = 1.05 - 1.55和1.63;95% CI = 1.20 - 2.20。曾经使用利尿剂与死亡率呈负相关,HR = 0.71;95% CI = 0.53 - 0.94。
高血压、糖尿病病史以及利尿剂、β受体阻滞剂、胰岛素和口服抗糖尿病药物的使用可能会影响卵巢癌患者的生存。了解这些观察结果的机制可能为治疗提供见解。